Evidence map›Paper›PMID 35536452›Full record

ArticleEndocrine2022

Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.

Iiro Kostiainen, Noora Karppinen, Piia Simonen, Milla Rosengård-Bärlund, Riikka Lindén, Maija Tarkkanen, Daniel Gordin, Janne Rapola, Camilla Schalin-Jäntti, Niina Matikainen

Abstract read
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Iiro KostiainenEndocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Noora KarppinenEndocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Piia SimonenCardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Milla Rosengård-BärlundEndocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Riikka LindénRadiology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Maija TarkkanenComprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Daniel GordinDepartment of Nephrology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Janne RapolaCardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Camilla Schalin-Jäntti *Endocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0002-2428-0161
Niina Matikainen *Endocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. niina.matikainen@hus.fi.ORCID 0000-0003-0041-1240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCarcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic markers for CS and CHD in a contemporary cohort of patients with small intestinal neuroendocrine tumours (SI-NETs).

methodsBiochemical characteristics, hepatic tumour load, measures of arterial and endothelial function, atherosclerosis, and transthoracic echocardiography were analysed in a prospective cross-sectional setting.

resultsAmong the 65 patients studied, 29 (45%) had CS (CS+ ), and 3 (5%) CHD. CS+ was characterised by significantly higher hepatic tumour load, S-5-HIAA and fP-CgA, higher frequency of diarrhoea and flushing, and more frequent PRRT compared to CS- (for all, P < 0.05). Central systolic, central mean, and central end-systolic blood pressures were significantly higher in CS+ than in CS- (for all, P < 0.05). Subjects with grades 2-4 TR had higher hepatic tumour burden, fP-CgA, and S-5-HIAA compared to those with grades 0-1 TR, but measures of vascular function did not differ. fP-CgA (P = 0.017) and S-5-HIAA (P = 0.019) but not proBNP increased significantly according to the severity of TR.

conclusionAlthough CS is common, the prevalence of CHD was found to be lower in a contemporary cohort of SI-NET patients than previously anticipated. Measures of arterial or endothelial function or carotid atherosclerosis do not identify subjects with mild TR. Echocardiography remains the most sensitive means to diagnose CHD in CS patients with high tumour burden and elevated CgA and 5-HIAA.

Indexed as

Carcinoid Heart DiseaseCarcinoid TumorIntestinal NeoplasmsLiver NeoplasmsMalignant Carcinoid SyndromeNeuroendocrine TumorsBiomarkersCross-Sectional StudiesHumansHydroxyindoleacetic AcidProspective StudiesBiomarkersHydroxyindoleacetic AcidArterial functionCarcinoid heart diseaseCarcinoid syndromeSmall intestinal neuroendocrine tumourTransthoracic echocardiography

Identifiers

PMID35536452
PMCPMC9242958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.